Ajay Bansal
University of Kansas Medical Center · University of Kansas · Veterans Affairs Medical Center and the University of Kansas Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ajay Bansal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06732388 · Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's EsophagusNational Cancer Institute (NCI) · recruiting · Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 · principal investigator
- Ph2NCT05419011 · Testing a Combination of Vaccines for Cancer Prevention in Lynch SyndromeNational Cancer Institute (NCI) · active not recruiting · Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome · principal investigator
- N/ANCT02464930 · Evaluation of MicroRNA Expression in Blood and Cytology for Detecting Barrett's Esophagus and Associated NeoplasiaMidwest Biomedical Research · unknown · Barrett's Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma · principal investigator
- N/ANCT00590434 · Yield and Safety of Colonoscopy in Patients Older Than 80 YearsMidwest Biomedical Research · completed · Colorectal Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Improving the Processes around Approval, Accrual and Translational Research in Cancer Prevention TrialsR50CA285494 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · fiscal years 2024 to 2026 · $144,141 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Flow Cytometry (FLOW)P30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Thomas A. Moore · fiscal years 2019 to 2026Named on NCT06732388
- Early Phase Clinical Cancer Prevention ConsortiumUG1CA242632 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Zora Djuric, Scott Michael Schuetze · fiscal years 2020 to 2026Named on NCT06732388, NCT05419011
- Cancer Center AdministrationP30CA060553 · NCI · NORTHWESTERN UNIVERSITY · PI Aleksandar Zafirovski · fiscal years 2019 to 2026Named on NCT05419011
- University of Arizona Cancer Prevention Clinical Trials NetworkUG1CA242596 · NCI · UNIVERSITY OF ARIZONA · PI Julie E Bauman, Patricia Ann Thompson · fiscal years 2019 to 2026Named on NCT05419011
- iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials ConsortiumUG1CA242609 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Eduardo Vilar Sanchez · fiscal years 2019 to 2026Named on NCT05419011
- The MW Cancer Prevention Clinical Trials NetworkUG1CA242635 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Lisa M Barroilhet · fiscal years 2020 to 2024Named on NCT05419011
- Northwestern Cancer Prevention ConsortiumUG1CA242643 · NCI · NORTHWESTERN UNIVERSITY · PI SEEMA Ahsan KHAN · fiscal years 2019 to 2026Named on NCT05419011
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:22 UTC. The ranking covers the 200 most relevant of 147 PubMed records, and a shared surname and initials can bring in a namesake. All 147 on PubMed
- Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.N Engl J Med · 2023459 citationsRCR 56.6
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.JAMA Dermatol · 2020421 citationsRCR 27.1
- Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device.J Heart Lung Transplant · 2015328 citationsRCR 13.3
- Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.J Am Acad Dermatol · 2020309 citationsRCR 20.3
- Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease.Transl Res · 2010293 citationsRCR 8.3
- 268 citationsRCR 10.2
- Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.N Engl J Med · 2024265 citationsRCR 47.0
- 237 citationsRCR 23.1
- Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.Nat Med · 2023216 citationsRCR 29.4
- Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial.Gastrointest Endosc · 2011214 citationsRCR 7.8